NEUROCRINE BIOSCIENCES INC — Form 8-K
Filed July 30, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Neurocrine completed acquisition of Soleno Therapeutics in May 2026 for $53.00/share ($2.9B equity value), adding VYKAT XR (hyperphagia treatment). Q2 2026 total revenue reached $959M (39% YoY growth): INGREZZA $716M (+15%), CRENESSITY $184M (+247%), VYKAT XR $54M (partial quarter post-acquisition). INGREZZA full-year guidance raised to $2.825-$2.875B from $2.7-$2.8B. Company secured $1.0B revolving credit facility; cash declined from $2.543B (Dec 2025) to $482M (June 2026) due to acquisition financing.
Why this rating
$2.9B acquisition is 31% of market cap—material M&A. Strong organic growth (+39% rev, INGREZZA +15%) offsets balance-sheet depletion. Multiple near-term clinical catalysts de-risk pipeline.
See more from July 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.